ProCE Banner Activity

Current Investigational Treatments Targeting HER3 in EGFR-Positive Post-TKI NSCLC

Slideset

Download these slides from an expert-led webinar on novel agents targeting HER3 in NSCLC

Released: April 03, 2023

Share

Provided by

ProCE Banner

Supporters

This activity is supported by an educational grant from

Daiichi Sankyo, Inc.

Faculty Disclosure

Helena Yu, MD: consultant/advisor/speaker: AbbVie, AstraZeneca, Black Diamond, Blueprint, Daiichi Sankyo, Janssen, Taiho.